Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing
SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.
"We're very pleased with each of the participants in this bridge financing that agreed to the extension of the maturity date," said Lisa Conte, Jaguar's Founder and CEO. "Each of these investors is committed to helping provide the resources needed to support Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer, our novel plant-based prescription medicine: our orphan disease intestinal failure program; our ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and our ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea."
To view the original terms of the bridge financing, as announced on March 26, 2025, please click here. To view the terms of the extension, please refer to the Form 8-K filed by the Company today, June 24, 2025, which can be viewed on the SEC Filings page of Jaguar's website. Click here to access the SEC Filings page of Jaguar's website.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer: the Company's orphan disease intestinal failure program; the Company's ongoing efforts to make crofelemer available for treatment of CTD in patients with metastatic breast cancer receiving selected targeted therapies; and the Company's ongoing development program to expand access for Canalevia in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
an hour ago
- Wall Street Journal
U.S. Futures Rise, Dollar Recovers Slightly on Trade Optimism
U.S. stock futures pointed to a higher open Friday after gains on Wall Street on Thursday with the S&P 500 and Nasdaq Composite closing just shy of record highs. The dollar recovered a touch on trade-deal optimism, while Treasury yields were little moved overnight. The final June University of Michigan consumer confidence survey lands later. –U.S. futures for the S&P 500, Dow Jones Industrial Average and Nasdaq were all up around 0.3% early in Europe.
Yahoo
an hour ago
- Yahoo
Jim Cramer on lululemon: 'I Don't Understand LULU'
lululemon athletica inc. (NASDAQ:LULU) is one of the 12 stocks on Jim Cramer's radar recently. When he asked about the company during the lightning round, Cramer commented: 'You know what… I did tell people that I thought it had bottomed, and I was dead wrong. And it's important to own up that I was wrong. I thought it had come down enough that perhaps it could have bounced, and I didn't get it right. So I'm going to punt and say I don't understand LULU. I got it wrong, and let's just move on.' A store employee in an athletic apparel store restocking merchandise. lululemon athletica (NASDAQ:LULU) designs and sells athletic apparel, footwear, and accessories for men and women. The company's products are made for activities such as yoga, running, and training. On June 6, Cramer expressed his shock over the company's recently reported quarter as he stated: 'I thought that LULU would do better. I thought that LULU would do better. I was quite surprised. I just, it was a bad conference call. It was a bad quarter. I am aghast to think that this could be… such a horrible situation. They had tariff problems. They had the wrong fashion. Everything went wrong for Calvin McDonald, and what can I say? I just don't think he's capable of being as bad as that stock was, 17 times earnings. It was a bad quarter, though. And you know… I've thought a lot about this, done a lot of soul searching, I am shocked at how they missed the quarter, and I wouldn't be surprised if there weren't some shakeups if that happened again.' While we acknowledge the potential of LULU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Are Quantum Computing Stocks Becoming the Next AI?
AI stocks soared last year, leading indexes higher. Quantum computing, like AI, offers game-changing technology -- making quantum stocks of interest to growth investors. 10 stocks we like better than D-Wave Quantum › Investors flocked to artificial intelligence (AI) stocks last year, and they drove market gains, leading the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average higher. Today, these players continue to advance, and they're joined by certain stocks in the high-potential field of quantum computing. In fact, quantum computing stocks might be following in the footsteps of AI stocks, becoming the next industry to lead market gains, and here's why. First, though, it's important to understand why AI grabbed the world's attention in recent years. This technology has the potential to revolutionize the way things are done -- from business to our daily lives -- by introducing more efficiency into processes. AI also can help companies develop new and better products -- from therapeutics to autonomous vehicles -- faster. So, AI can be a gamechanger, and experts have even likened the technology to the development of the steam engine, or in more recent days, the internet. Companies powering AI, such as AI chip leader Nvidia and networking giant Broadcom have seen their shares surge -- and so have companies offering AI infrastructure, like Amazon, or those developing AI platforms and applying them to their businesses. A good example of that is Meta Platforms, which trained AI model Llama, a tool that powers its popular AI assistant. Today, AI continues to be an interesting growth story, and there are plenty of chapters left in this exciting book. But quantum computing may be even earlier in its growth story -- and also promises to become a game changer. Investors generally like getting in on an investing theme early to fully benefit as it develops. So, what exactly is quantum computing? It's a type of computing that relies on the principles of quantum mechanics, or how subatomic particles interact. In quantum computing, the computing is done by qubits rather than the bits used in traditional computing. Their ability to process data as a zero, a 1, or both at the same time, and the combining of many of these qubits allows for the solving of problems that have been impossible for classical computers. Several pure play companies are publicly traded and are working toward making this process useful for real world problems. In fact, D-Wave Quantum (NYSE: QBTS) recently launched its Advantage2 quantum computer to be used in fields such as business optimization or AI. D-Wave, thanks to sales of its Advantage system and services, in the recent quarter said revenue soared 500% to a record $15 million -- the increase in revenue shows customers are interested in such technology, and the revenue level shows there still is plenty of room for gains as this technology develops. Though D-Wave and others such as Rigetti Computing and IonQ are generating revenue from certain systems and services, quantum computers haven't yet even come close to reaching their full potential. The good news here is that means, if research and development goes well, revenue could explode higher down the road -- making now an excellent time to get in on these players. The big difference between AI and quantum computing today is AI is more regularly and easily applied to real world problems, while quantum has significant challenges to conquer. For example, qubits are fragile and can only hold information for a short period of time. Other challenges are error rates and difficulty scaling quantum systems. All of this makes quantum computing stocks higher risk right now than AI stocks -- but, considering the promise of quantum computing, investing in these stocks could lead to enormous returns over time if the technology is successful. What does this mean for you as an investor? If you're an aggressive investor looking for the next big thing in technology, you may consider buying shares of some of the leading pure play companies such as the players I've mentioned above. If you're cautious but still interested in the field, you could opt for well-established tech giants such as Alphabet or Microsoft that also have quantum computing programs. It's still too early to say how successful quantum computing will be over time, but companies have made progress recently, and potential is strong. That means quantum computing stocks could become the AI stocks of 2025 -- and help lead the overall market higher. Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Are Quantum Computing Stocks Becoming the Next AI? was originally published by The Motley Fool Sign in to access your portfolio
